{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:07:38Z","timestamp":1772186858948,"version":"3.50.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Institute of Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The development of non-hormonal contraceptives is critical to increase options for women. In combination with prevention against sexually transmitted infections, they can become an important component of multipurpose prevention technologies (MPTs) which address multiple reproductive health needs with a single product. Resulting from multiple rounds of expert consultations, this framework aims to guide the development of non-hormonal contraceptive MPTs. Key informant interviews with experts in family planning and HIV and STI prevention and MPT product developers and funders from around the globe were conducted, reviewed, and coded. Identified key themes were discussed by experts at the November 2019 Eunice Kennedy Shriver National Institute of Child Health and Human Development Contraceptive Development Meeting in Houston, Texas. Seven action strategies were identified to address key research gaps and priorities for advancing the field. They highlight the importance of identifying target populations, a systematic approach to collaborative research, and leveraging knowledge from other fields, including regulatory and patenting, manufacturing, and commercialization expertise. Employing expanded target product profiles and setting go\/no-go decisions for non-hormonal MPTs will help to prioritize the most promising candidates in the drug development pipeline. Further, they call for optimizing investments and engagement of stakeholders from public and private sectors. These action strategies aim to facilitate collaboration and innovation amongst multidisciplinary MPT stakeholders. Paramount to success will be enhancing strategic alliances and reconciling the essential social\u2013behavioral context and market forces that drive product use with the complexities of research and development, regulatory approval, and commercialization.<\/jats:p>","DOI":"10.1093\/biolre\/ioaa092","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T08:25:34Z","timestamp":1591863934000},"page":"289-298","source":"Crossref","is-referenced-by-count":16,"title":["Towards a roadmap to advance non-hormonal contraceptive multipurpose prevention technologies: strategic insights from key stakeholders\u2020"],"prefix":"10.1093","volume":"103","author":[{"given":"Anke","family":"Hemmerling","sequence":"first","affiliation":[{"name":"The Initiative for Multipurpose Prevention Technologies, A Project of CAMI Health, Public Health Institute, Sacramento, CA, USA"},{"name":"Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Christopher","sequence":"additional","affiliation":[{"name":"The Initiative for Multipurpose Prevention Technologies, A Project of CAMI Health, Public Health Institute, Sacramento, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany","family":"Young Holt","sequence":"additional","affiliation":[{"name":"The Initiative for Multipurpose Prevention Technologies, A Project of CAMI Health, Public Health Institute, Sacramento, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"2020080407010749900_ref1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1056\/NEJMp1906733","article-title":"Population and the environment\u2014Time for another contraception revolution","volume":"381","author":"Anderson","year":"2019","journal-title":"N Engl J Med"},{"key":"2020080407010749900_ref2","volume-title":"Ten Top Issues for Women\u2019s Health","author":"Bustreo"},{"key":"2020080407010749900_ref3","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","article-title":"Contemporary hormonal contraception and the risk of breast cancer","volume":"377","author":"M\u00f8rch","year":"2017","journal-title":"N Engl J Med"},{"key":"2020080407010749900_ref4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11154-011-9182-4","article-title":"Metabolic effects of contraceptive steroids","volume":"12","author":"Sitruk-Ware","year":"2011","journal-title":"Rev Endocr Metab Disord"},{"key":"2020080407010749900_ref5","volume-title":"Multipurpose Prevention Technologies (MPTs)","author":"Initiative for MPTs"},{"key":"2020080407010749900_ref6","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1080\/13625187.2018.1508650","article-title":"A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV","volume":"23","author":"Young Holt","year":"2018","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"2020080407010749900_ref7","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/s0020-7292(99)00142-3","article-title":"Public\/private-sector collaboration in contraceptive research and development: Summary and historical perspective","volume":"67","author":"Spieler","year":"1999","journal-title":"Int J Gynaecol Obstet"},{"key":"2020080407010749900_ref8","volume-title":"Unintended Pregnancy in the United States","author":"Guttmacher Institute","year":"2019"},{"key":"2020080407010749900_ref9","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/OLQ.0000000000000193","article-title":"The estimated lifetime probability of acquiring human papillomavirus in the United States","volume":"41","author":"Chesson","year":"2014","journal-title":"Sex Transm Dis"},{"key":"2020080407010749900_ref10","volume-title":"HIV Among Women","author":"Centers for Disease Control and Prevention","year":"2020"},{"key":"2020080407010749900_ref11","article-title":"CDC adds new HIV and social determinants of health indicators to NCHHSTP\u2019s AtlasPlus. HIV.gov","author":"Mermin","year":"2018"},{"key":"2020080407010749900_ref12","doi-asserted-by":"publisher","first-page":"1\u201320","DOI":"10.1155\/2014\/350195","article-title":"Mucosal immunity in the female genital tract, HIV\/AIDS","volume":"2014","author":"Reis Machado","year":"2014","journal-title":"Biomed Res Int"},{"key":"2020080407010749900_ref13","article-title":"Postpartum family planning: Essential for ensuring health of women and their babies","author":"World Health Organization","year":"2018"},{"key":"2020080407010749900_ref14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1728-4465.2014.00393.x","article-title":"Intended and unintended pregnancies worldwide in 2012 and recent trends","volume":"45","author":"Sedgh","year":"2014","journal-title":"Stud Fam Plan"},{"key":"2020080407010749900_ref15","first-page":"e677","article-title":"Mood and sexual side effects of hormonal contraception","volume":"58","author":"Wiebe","year":"2012","journal-title":"Can Fam Physician"},{"key":"2020080407010749900_ref16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3109\/13625187.2015.1137281","article-title":"Non-hormonal and hormonal intrauterine contraception: Survey of patients\u2019 perceptions in four Latin American countries","volume":"21","author":"da","year":"2016","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"2020080407010749900_ref17","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.contraception.2014.05.111","article-title":"Patient preferences regarding the use of nonhormonal contraceptive methods","volume":"90","author":"Joy","year":"2014","journal-title":"Contraception"},{"key":"2020080407010749900_ref18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1728-4465.2014.00382.x","article-title":"Reasons for contraceptive nonuse among women having unmet need for contraception in developing countries","volume":"45","author":"Sedgh","year":"2014","journal-title":"Stud Fam Plan"},{"key":"2020080407010749900_ref19","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1363\/4419412","article-title":"Contraceptive features preferred by women at high risk of unintended pregnancy","volume":"44","author":"Lessard","year":"2012","journal-title":"Perspect Sex Reprod Health"},{"key":"2020080407010749900_ref20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/jfprhc-2014-100956","article-title":"Hormonal contraception and regulation of menstruation: A study of young women\u2019s attitudes towards having a period","volume":"41","author":"Newton","year":"2015","journal-title":"J Fam Plann Reprod Health Care"},{"key":"2020080407010749900_ref21","doi-asserted-by":"publisher","first-page":"CD003988","DOI":"10.1002\/14651858.CD003988.pub2","article-title":"Combined hormonal versus nonhormonal versus progestin-only contraception in lactation","volume":"Mar 20","author":"Lopez","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2020080407010749900_ref22","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/AOG.0000000000003089","article-title":"Side effects and health benefits of depot medroxyprogesterone acetate: A systematic review","volume":"133","author":"Dianat","year":"2019","journal-title":"Obstet Gynecol"},{"key":"2020080407010749900_ref23","doi-asserted-by":"publisher","first-page":"CD008815","DOI":"10.1002\/14651858.CD008815.pub4","article-title":"Progestin-only contraceptives: Effects on weight","author":"Lopez","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2020080407010749900_ref24","doi-asserted-by":"publisher","first-page":"i2002","DOI":"10.1136\/bmj.i2002","article-title":"Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: Cohort study","volume":"353","author":"Weill","year":"2016","journal-title":"BMJ"},{"key":"2020080407010749900_ref25","volume-title":"STDs Continue to Rise in the U.S. Press Release","author":"Centers for Disease Control and Prevention","year":"2019"},{"key":"2020080407010749900_ref26","doi-asserted-by":"publisher","first-page":"e0143304","DOI":"10.1371\/journal.pone.0143304","article-title":"Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting","volume":"10","author":"Newman","year":"2015","journal-title":"PLoS One"},{"key":"2020080407010749900_ref27","volume-title":"Sexually Transmitted Infections (STIs)","author":"World Health Organization"},{"key":"2020080407010749900_ref28","volume-title":"Women\u2019s and Girls\u2019 Health Across the Life Course","author":"World Health Organization"},{"key":"2020080407010749900_ref29","doi-asserted-by":"publisher","first-page":"e25064","DOI":"10.1002\/jia2.25064","article-title":"The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa","volume":"21","author":"Quaife","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"2020080407010749900_ref30","doi-asserted-by":"publisher","first-page":"e25094","DOI":"10.1002\/jia2.25094","article-title":"The tablets, ring, injections as options (TRIO) study: What young African women chose and used for future HIV and pregnancy prevention","volume":"21","author":"van der Straten","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"2020080407010749900_ref31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2147\/IJWH.S193905","article-title":"Engaging study participants in interpreting results: Lessons from the TRIO study in Kenya and South Africa","volume":"2019","author":"Agot","year":"2019","journal-title":"Int J Women's Health"},{"key":"2020080407010749900_ref32","article-title":"End-users\u2019 product preference across three multipurpose prevention technology delivery forms: Baseline results from young women in Kenya and South Africa","author":"Weinrib","year":"2017","journal-title":"AIDS Behav"},{"key":"2020080407010749900_ref33","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/QAI.0000000000001945","article-title":"Young women\u2019s stated preferences for biomedical HIV prevention: Results of a discrete choice experiment in Kenya and South Africa","volume":"80","author":"Minnis","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020080407010749900_ref34","doi-asserted-by":"publisher","first-page":"334ps9","DOI":"10.1126\/scitranslmed.aaf0685","article-title":"The human vaccines project: A roadmap for cancer vaccine development","volume":"8","author":"Romero","year":"2016","journal-title":"Sci Transl Med"},{"key":"2020080407010749900_ref35","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/790154","article-title":"Developing multipurpose reproductive health technologies: An integrated strategy","author":"Harrison","year":"2013","journal-title":"AIDS Res Treat"},{"key":"2020080407010749900_ref36","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1016\/j.vaccine.2016.03.111","article-title":"The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps","volume":"34","author":"Gottlieb","year":"2016","journal-title":"Vaccine"},{"key":"2020080407010749900_ref37","volume-title":"Delphi Method","author":"RAND Corporation","year":"2020"},{"key":"2020080407010749900_ref38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2325958219841366","article-title":"Two birds with one stone: Health care providers\u2019 perspectives about prevention technologies in Kenya and South Africa","volume":"18","author":"Lutnick","year":"2019","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2020080407010749900_ref39","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1089\/aid.2015.0275","article-title":"Perceptibility and the \u201cchoice experience\u201d: User sensory perceptions and experiences inform vaginal prevention product design","volume":"32","author":"Guthrie","year":"2016","journal-title":"AIDS Res Hum Retrovir"},{"key":"2020080407010749900_ref40","doi-asserted-by":"publisher","first-page":"S222","DOI":"10.1097\/QAI.0000000000002215","article-title":"Insights for implementation science from 2 multiphased studies with end-users of potential multipurpose prevention technology and HIV prevention products","volume":"82","author":"Minnis","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020080407010749900_ref41","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12905-018-0657-2","article-title":"Qualitative exploration of intrinsic and extrinsic factors that influence acceptability of semisoft vaginal suppositories","volume":"18","author":"Zaveri","year":"2018","journal-title":"BMC Womens Health"},{"key":"2020080407010749900_ref42","volume-title":"Toward a Roadmap for Biomedical HIV Prevention Investment Standards: Strategic Insights from Key Industry Stakeholders","author":"Initiative for MPTs","year":"2019"},{"key":"2020080407010749900_ref43","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrd2030","article-title":"Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond","volume":"5","author":"Ghofrani","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"2020080407010749900_ref44","volume-title":"Paediatric Antiretroviral Drug Optimization (PADO) Meeting 4. WHO","author":"World Health Organization","year":"2018"},{"key":"2020080407010749900_ref45","volume-title":"PAR-16-405: Single-Site Investigator-Initiated Clinical Trials (R61\/R33)","author":"National Institutes of Health","year":"2016"},{"key":"2020080407010749900_ref46","volume-title":"Commercialization Accelerator Program","author":"National Institutes of Health","year":"2020"},{"key":"2020080407010749900_ref47","volume-title":"Hormonal Contraceptive Market Size, Share & Trends Analysis Report by Method (Pill, Intrauterine Device (IUD), Patch, Implant, Vaginal Ring, Injectable), by Region, and Segment Forecasts, 2019\u20132026","author":"Grand View Research","year":"2019"},{"key":"2020080407010749900_ref48","volume-title":"Global Access","author":"Bill & Melinda Gates Foundation","year":"2020"},{"key":"2020080407010749900_ref49","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1208\/s12249-010-9521-x","article-title":"Considerations in developing a target product profile for parenteral pharmaceutical products","volume":"11","author":"Lambert","year":"2010","journal-title":"AAPS PharmSciTech"},{"key":"2020080407010749900_ref50","volume-title":"MPT Dosage-Form Specific Target Product Profiles (TPPs)","author":"Initiative for MPTs","year":"2014"}],"container-title":["Biology of Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/biolreprod\/advance-article-pdf\/doi\/10.1093\/biolre\/ioaa092\/33495510\/ioaa092.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/biolreprod\/article-pdf\/103\/2\/289\/33563201\/ioaa092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/biolreprod\/article-pdf\/103\/2\/289\/33563201\/ioaa092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T11:03:20Z","timestamp":1596539000000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/biolreprod\/article\/103\/2\/289\/5855537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,6,10]]},"published-print":{"date-parts":[[2020,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/biolre\/ioaa092","relation":{},"ISSN":["0006-3363","1529-7268"],"issn-type":[{"value":"0006-3363","type":"print"},{"value":"1529-7268","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,6,10]]}}}